Accordingly, serum measurement of TREM2 in two independent cohorts, including biopsy-proven MASLD patients and subjects with non-invasive MASLD diagnosis, resulted in a good biomarker for MASLD advanced stages, potentially becoming a candidate target for therapeutic interventions [71]. This evidence concerns the gene TREM2 and metabolic dysfunction-associated steatotic liver disease.